Personalis Debt to Equity Ratio 2018-2024 | PSNL
Current and historical debt to equity ratio values for Personalis (PSNL) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Personalis debt/equity for the three months ending September 30, 2024 was 0.00.
| Personalis Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-09-30 |
$0.07B |
$0.17B |
0.44 |
| 2024-06-30 |
$0.07B |
$0.11B |
0.65 |
| 2024-03-31 |
$0.08B |
$0.12B |
0.62 |
| 2023-12-31 |
$0.10B |
$0.13B |
0.74 |
| 2023-09-30 |
$0.08B |
$0.15B |
0.50 |
| 2023-06-30 |
$0.07B |
$0.18B |
0.41 |
| 2023-03-31 |
$0.08B |
$0.19B |
0.41 |
| 2022-12-31 |
$0.08B |
$0.22B |
0.34 |
| 2022-09-30 |
$0.08B |
$0.24B |
0.31 |
| 2022-06-30 |
$0.09B |
$0.27B |
0.35 |
| 2022-03-31 |
$0.09B |
$0.29B |
0.33 |
| 2021-12-31 |
$0.09B |
$0.31B |
0.28 |
| 2021-09-30 |
$0.08B |
$0.33B |
0.25 |
| 2021-06-30 |
$0.05B |
$0.34B |
0.13 |
| 2021-03-31 |
$0.05B |
$0.35B |
0.14 |
| 2020-12-31 |
$0.05B |
$0.20B |
0.26 |
| 2020-09-30 |
$0.05B |
$0.20B |
0.22 |
| 2020-06-30 |
$0.05B |
$0.09B |
0.56 |
| 2020-03-31 |
$0.05B |
$0.10B |
0.53 |
| 2019-12-31 |
$0.05B |
$0.11B |
0.47 |
| 2019-09-30 |
$0.05B |
$0.11B |
0.43 |
| 2019-06-30 |
$0.08B |
$0.12B |
0.64 |
| 2019-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2018-12-31 |
$0.00B |
|
0.00 |
| 2018-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2018-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2017-12-31 |
$0.00B |
$0.00B |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.261B |
$0.073B |
|
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|
